Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study

2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Norbert-Claude Gorin ◽  
Françoise Isnard ◽  
Laurent Garderet ◽  
Souhila Ikhlef ◽  
Selim Corm ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia

Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia

2015 ◽  
Vol 15 ◽  
pp. S5
Author(s):  
Koji Sasaki ◽  
Susan O’Brien ◽  
Deborah Thomas ◽  
Maria Khouri ◽  
Musa Yilmaz ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
Frontline Therapy

A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.

1991 ◽  
Vol 9 (1) ◽  
pp. 139-144 ◽  
Author(s):  
J Ochs ◽  
J Rodman ◽  
M Abromowitch ◽  
R Kavanagh ◽  
M Harris ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
Therapeutic Index ◽  
Small Sample ◽  
Therapeutic Window ◽  
Infusion Schedule ◽  
Small Sample Sizes

Teniposide (VM-26) can increase intracellular methotrexate (MTX) and its polyglutamate derivatives in vitro and thus has the potential to improve the therapeutic index of regimens containing MTX. In this phase II study, children and adolescents with acute lymphoblastic leukemia (ALL) in first or second marrow relapse were randomly assigned to receive either simultaneous (n = 11) or sequential (n = 12) continuous infusions of MTX and VM-26 prior to reinduction. Infusions of VM-26 were begun 12 hours after completion of MTX infusion in the sequential group. Dosages were individually adjusted to maintain plasma concentration levels of 10 microns for MTX and 15 microns for VM-26; total infusion times were 24 and 72 hours, respectively. Significant toxicity in the first six patients who received the scheduled 72-hour VM-26 infusion (including one drug-related death) prompted a 50% reduction in infusion duration. The reduced dose was associated with similar but more manageable toxicity. Examination of bone marrow aspirates 10 days after therapy was begun showed one complete and two partial marrow remissions; a fourth patient who had an aplastic marrow on day 10 received no further chemotherapy and had a complete remission (CR) documented on day 31. There was no obvious clinical advantage associated with either infusion schedule, although small sample sizes preclude definitive conclusions. The 17% response rate to the MTX/VM-26 therapeutic window in patients with refractory disease suggests the need for further investigation to evaluate alternative schedules and concomitant therapy for this drug combination.

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia

2000 ◽  
Vol 24 (3) ◽  
pp. 183-187 ◽  
Author(s):  
Peter J. Rosen ◽  
Cathryn Rankin ◽  
David R. Head ◽  
David H. Boldt ◽  
Frederick W. Luthardt ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
High Dose ◽  
Adult Acute Lymphoblastic Leukemia

DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study

2009 ◽  
Vol 83 (6) ◽  
pp. 512-518 ◽  
Author(s):  
Christine Dudler ◽  
Mario Bargetzi ◽  
Andr�� Tichelli ◽  
Alois Gratwohl ◽  
Jakob R. Passweg ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
Adult Patients

scholarly journals A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

2009 ◽  
Vol 53 (6) ◽  
pp. 978-983 ◽  
Author(s):  
Anne L. Angiolillo ◽  
Alice L. Yu ◽  
Gregory Reaman ◽  
Ashish M. Ingle ◽  
Rita Secola ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
Oncology Group ◽  
Group Report

scholarly journals Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

2014 ◽  
Vol 90 (2) ◽  
pp. 120-124 ◽  
Author(s):  
Tapan M. Kadia ◽  
Hagop M. Kantarjian ◽  
Deborah A. Thomas ◽  
Susan O'Brien ◽  
Zeev Estrov ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia

High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL–Positive Acute Lymphoblastic Leukemia: A Phase II Study by the Japan Adult Leukemia Study Group

2006 ◽  
Vol 24 (3) ◽  
pp. 460-466 ◽  
Author(s):  
Masamitsu Yanada ◽  
Jin Takeuchi ◽  
Isamu Sugiura ◽  
Hideki Akiyama ◽  
Noriko Usui ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Complete Remission ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Lymphoblastic Leukemia ◽  
Remission Induction ◽  
Severe Toxicity ◽  
Newly Diagnosed ◽  
Hematopoietic Stem ◽  
Short Period

Purpose A novel therapeutic approach is urgently needed for BCR-ABL–positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib. Patients and Methods A phase II study of imatinib-combined chemotherapy was conducted for newly diagnosed BCR-ABL–positive ALL in adults. Eighty patients were entered into the trial between September 2002 and January 2005. Results Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%. The profile and incidence of severe toxicity were not different from those associated with our historic chemotherapy-alone regimen. Relapse occurred in 20 patients after median CR duration of 5.2 months. Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR. The 1-year event-free and overall survival (OS) rates were estimated to be 60.0%, and 76.1%, respectively, which were significantly better than those for our historic controls treated with chemotherapy alone (P < .0001 for both). Among the current trial patients, the probability for OS at 1 year was 73.3% for those who underwent allogeneic HSCT, and 84.8% for those who did not. Conclusion Our results demonstrated that imatinib-combined regimen is effective and feasible for newly diagnosed BCR-ABL–positive ALL. Despite a relatively short period of observation, a major potential of this treatment is recognized. Longer follow-up is required to determine its overall effect on survival.

Sign in / Sign up

Export Citation Format

Share Document